Although researchers can monitor brain activity associated with perception, pain, and awareness, it remains unclear which neural pathways are tied to the origins of consciousness.
Laboratory tests of a novel serotonin-binding compound have revealed an unexpected disconnect between receptor activation and behavior, raising new questions about how psychedelic effects emerge in the brain.
New research reveals how psilocybin reshapes connections across the brain, helping explain how it can ease depression symptoms for weeks or even months.
More than half of Americans, roughly 54% of the population, are living with a neurological disease or disorder, according findings detailed in a new study.
Spanish brain-computer interface (BCI) company INBRAIN Neuroelectronics has announced its collaboration with Microsoft to explore AI applications for real-time brain-computer interface therapeutics.
Scientists have found that immersive virtual reality may offer a way to replicate some of the psychological benefits associated with psychedelic substances, but without the use of any drugs.
Neuralink has moved to validate its controversial brain-implant technology in the scientific arena by submitting its first study for peer review and publication.
INBRAIN Neuroelectronics has partnered with Mayo Clinic to advance graphene-based brain-computer interface therapies, expanding into the U.S. while navigating differing European and FDA regulatory pathways.
The rapidly expanding brain-computer interface (BCI) field is not only driving cutting-edge neuroscience but also fueling a competitive race for market dominance.